SG11202011651SA - Biomarkers for determining the effectiveness of immune checkpoint inhibitors - Google Patents

Biomarkers for determining the effectiveness of immune checkpoint inhibitors

Info

Publication number
SG11202011651SA
SG11202011651SA SG11202011651SA SG11202011651SA SG11202011651SA SG 11202011651S A SG11202011651S A SG 11202011651SA SG 11202011651S A SG11202011651S A SG 11202011651SA SG 11202011651S A SG11202011651S A SG 11202011651SA SG 11202011651S A SG11202011651S A SG 11202011651SA
Authority
SG
Singapore
Prior art keywords
biomarkers
effectiveness
determining
immune checkpoint
checkpoint inhibitors
Prior art date
Application number
SG11202011651SA
Inventor
Hiroyoshi Nishikawa
Yosuke Togashi
Yukiya OHYAMA
Takao Yoshida
Kazuhiko Takeda
Kenichi Koda
Atsushi Honda
Atsushi Oyagi
Toru Kakinuma
Masayuki Murata
Original Assignee
Ono Pharmaceutical Co
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co, Nat Cancer Ct filed Critical Ono Pharmaceutical Co
Publication of SG11202011651SA publication Critical patent/SG11202011651SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202011651SA 2018-05-31 2019-05-30 Biomarkers for determining the effectiveness of immune checkpoint inhibitors SG11202011651SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018105017 2018-05-31
JP2018189370 2018-10-04
PCT/JP2019/021633 WO2019230919A1 (en) 2018-05-31 2019-05-30 Biomarker for judging efficacy of immune checkpoint inhibitor

Publications (1)

Publication Number Publication Date
SG11202011651SA true SG11202011651SA (en) 2020-12-30

Family

ID=68697509

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011651SA SG11202011651SA (en) 2018-05-31 2019-05-30 Biomarkers for determining the effectiveness of immune checkpoint inhibitors

Country Status (14)

Country Link
US (1) US20210198361A1 (en)
EP (1) EP3804758A4 (en)
JP (1) JP7388635B2 (en)
KR (1) KR20210018253A (en)
CN (1) CN112203688A (en)
AU (1) AU2019277632A1 (en)
BR (1) BR112020024404A2 (en)
CA (1) CA3101766A1 (en)
IL (1) IL278967A (en)
MX (1) MX2020012939A (en)
PH (1) PH12020552011A1 (en)
SG (1) SG11202011651SA (en)
TW (1) TW202015732A (en)
WO (1) WO2019230919A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2161336T1 (en) * 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
MX2022001434A (en) * 2019-08-05 2022-02-22 Ono Pharmaceutical Co Biomarker for accessing efficacy of immune checkpoint inhibitor.
WO2022017435A1 (en) * 2020-07-22 2022-01-27 信达生物制药(苏州)有限公司 SERIES OF BIOMARKERS OF CONSENSUS SEQUENCES IN CDR3 SEQUENCE OF TCR-β CHAIN AND APPLICATION THEREOF
EP3944863A1 (en) * 2020-07-28 2022-02-02 Fundació Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM) Combined therapy against cancer
CN113125751B (en) * 2021-04-12 2022-11-08 首都医科大学附属北京世纪坛医院 Method for predicting PD-L1 level in breast cancer tumor tissue by peripheral blood PD-1/PD-L1
CN114159557A (en) * 2021-11-09 2022-03-11 北京东方百泰生物科技股份有限公司 Combined medicine composition for treating tumor diseases and application thereof
WO2023235839A1 (en) * 2022-06-02 2023-12-07 Immunext, Inc. Development of vista-centric tumor immunophenotyping for identification of potential biomarkers for anti-vista therapy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (en) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
DE60033530T2 (en) 1999-08-24 2007-10-31 Medarex Inc. HUMAN ANTIBODIES TO CTLA-4 AND THEIR USES
BRPI0613361A2 (en) 2005-07-01 2011-01-04 Medarex Inc isolated human monoclonal antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, transgenic mouse, method for modulating an immune response in an individual, method for inhibiting tumor cell growth in an individual, method for treating an infectious disease in a subject, a method for enhancing an immune response to an antigen in a subject, a method for treating or preventing an inflammatory disease in a subject, and a method for preparing the anti-pd-11 antibody
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014194293A1 (en) * 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
ES2642074T3 (en) 2013-09-04 2017-11-15 Bristol-Myers Squibb Company Useful compounds as immunomodulators
AU2014346852A1 (en) * 2013-11-05 2016-06-16 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CN106999536B (en) 2014-09-11 2020-11-27 百时美施贵宝公司 Macrocyclic inhibitors of PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
EP3233123A4 (en) * 2014-12-16 2018-05-09 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
ES2928164T3 (en) 2015-10-19 2022-11-15 Incyte Corp Heterocyclic compounds as immunomodulators
CA3005727A1 (en) 2015-11-19 2017-05-26 Incyte Corporation Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators
WO2017106634A1 (en) 2015-12-17 2017-06-22 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
PE20230731A1 (en) 2015-12-22 2023-05-03 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
AR108396A1 (en) 2016-05-06 2018-08-15 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
CN107417564A (en) 2016-05-23 2017-12-01 中国医学科学院药物研究所 Phenylate analog derivative and its preparation method and pharmaceutical composition and purposes
ES2905980T3 (en) 2016-05-26 2022-04-12 Incyte Corp Heterocyclic compounds as immunomodulators
US20180055882A1 (en) * 2016-08-04 2018-03-01 The Regents Of The University Of California Functional immunophenotyping of leukocytes in human tissues

Also Published As

Publication number Publication date
CA3101766A1 (en) 2019-12-05
US20210198361A1 (en) 2021-07-01
IL278967A (en) 2021-01-31
EP3804758A4 (en) 2022-03-02
PH12020552011A1 (en) 2021-06-14
JP7388635B2 (en) 2023-11-29
EP3804758A1 (en) 2021-04-14
JPWO2019230919A1 (en) 2021-07-08
TW202015732A (en) 2020-05-01
BR112020024404A2 (en) 2021-03-02
KR20210018253A (en) 2021-02-17
AU2019277632A1 (en) 2020-12-24
CN112203688A (en) 2021-01-08
WO2019230919A1 (en) 2019-12-05
MX2020012939A (en) 2021-02-15

Similar Documents

Publication Publication Date Title
IL278967A (en) Biomarkers for determining the effectiveness of immune checkpoint inhibitors
IL263542A (en) Bispecific checkpoint inhibitor antibodies
IL283639A (en) Kif18a inhibitors
IL292642A (en) Ras inhibitors
IL292643A (en) Ras inhibitors
IL292644A (en) Ras inhibitors
IL277006A (en) Cd73 inhibitors
ZA201908549B (en) Checkpoint inhibitor bispecific antibodies
IL304348A (en) Cd73 inhibitors
IL265274A (en) Antibody and checkpoint inhibitor combination therapy
IL276813A (en) Arginase inhibitors
IL290266A (en) Biomarkers for determining the efficacy of immune checkpoint inhibitors
IL277794A (en) Atf6 inhibitors and uses thereof
ZA202107835B (en) Prc2 inhibitors
IL276013A (en) Pi4kiiibeta inhibitors
EP3854224A4 (en) Immune checkpoint inhibitor
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP3385698C0 (en) Method for the analysis of surface measurements
SG11202106708VA (en) Method of predicting for benefit from immune checkpoint inhibition therapy
GB2568130B (en) Method for determining the presence of an acidic sulfide species
GB201907550D0 (en) Detection of biomarkers
PT3614349T (en) Method for inspecting the surface of coins
IL279000A (en) Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201809939D0 (en) Eastase inhibitor